Using RWE to benefit pricing and patient access: an interview with Ulf Staginnus

In this interview, Ulf Staginnus (Blueprint Medicines, MA, USA) discusses the impact of real-world evidence (RWE) on pricing and market access, alongside the needs of stakeholders. There is also some insight into the future of pricing and market access, both in how new approaches may emerge in the coming years alongside evolution with time. Please could you introduce yourself, your organization(s) and provide a summary of your career to date? I am an economist (University of Bayreuth, Germany) with 25 years of international experience in the field of market access, pharmacoeconomics, pricing and reimbursement, as well as health technology valuations within...